Alfasan Uganda, Makerere University Partner To Manufacturer Anti-Tick Vaccine
Pressug Online News Publication
Makerere University together with Alfasan Uganda limited partnered to manufacturers Human and Vetinary medicine to finalize clinical trials of Africa’s first anti-tick vaccine.
This first ever vaccine was developed by scientists from the Makerere University College of Vetinary Medicine, Animal Resources and Bio-Security (Mak COVAB) with intention to reduce on the farmers expenditure while buying acaricides that are used for spraying ticks, animals.
Prof. Barnabas Nawangwe, the Vice Chancellor of Makerere University while speaking at the signing Memorandum of understanding (MOU) appreciated the scientists for the work done and the continued innovations that now takes the University, international and led Africa in research.
“This vaccine is one of the most advanced scientific endeavors, takes up the University capacity level and it's a self speaking testimony that Makerere reached on". Said Nawangwe adding that the vaccine has successfully passed the pre-clinical trials and now moved to the second stage of clinical trials, which will be conducted at Alfasan Uganda Factories.
Dr. Margaret Saimo Kahwa the principal investigator says that the vaccine meant to develop an effective, affordable and safe anti-tick vaccine that will help to protect cattle from risk of acaricides resistant ticks.
“this will add investment in the sector, increase food security, household income and a multiplier effect on export of livestock products,” Said Margaret
Currently, Uganda is being ravaged by ticks, that are resistant to the current acaricides, according to Scientists. 70% of the 15 million livestock die of tick-borne caused related diseases.
Dr. Stephen Birungi, the Managing Director of Alfasan Uganda Ltd the owners Alfasan Uganda Vetinary factory said the mission of the anti-tick vaccine production was to develop a recombinant vaccine using proteins identified from local ticks.
“The package in the control of ticks and tick-borne diseases, through vaccination. The anti-tick vaccine would reduce the burden of ticks to improve and enhance the health and wellbeing of livestock in Uganda in terms of development". So Dr. Stephen.
THE SIGNED MEMORANDUM OF UNDERSTANDING.
According to Dr. Birungi, the MOU will move for 10 years (2021-2030) and will bring to bear synergies that exist between the two organizations; Mak-COVAB is a premier teaching and research institution while Alfasan Uganda limited has a manufacturing factory of GMP approved by national drug authority.
The vaccine production of this product will migrate to Alfasan Uganda facilities in order to comply with NDA requirement of Good Manufacturing Practices (GMP). However once the clinical trials are done, he said the anti-tick vaccines will be ready for use. Meanwhile alfasan Uganda limitedhas the capacity of producing over 30 million vaccines to manage the two doses of the over 15 million livestock in Uganda.
The Clinical trials which will take about six months are successful, Alfasan Uganda limited and Makerere University will now attain a certificate from the NDA, which will declare them to go commercial, and the vaccine will be produced on market.
For any comments or story please contact us at firstname.lastname@example.org or send a watspp on +256702767744 or +256750660801